RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting

<strong>Background: </strong>RH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, desi...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Healer, J, Thompson, JK, Mackwell, KL, Browne, CD, Seager, BA, Ngo, A, Lowes, KN, Silk, SE, Pulido, D, King, LDW, Christen, JM, Noe, AR, Kotraiah, V, Masendycz, PJ, Rajagopalan, R, Lucas, L, Stanford, MM, Soisson, L, Diggs, C, Miller, R, Youll, S, Wycherley, K, Draper, SJ, Cowman, AF
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: Frontiers Media 2022